Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

MetroGel 1% Hydration Study: A Kinetic Regression Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00436527

Enrollment

Registered

2007-02-19

Start date

2006-08-31

Completion date

2006-08-31

Last updated

2022-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Brief summary

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

Detailed description

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application as measured by the Corneometer CM 825.

Interventions

DRUGMetronidazole gel 1%

Applied once to a test site on the right or left cheek (as determined by a randomization design)

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions

Exclusion criteria

* Individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis

Design outcomes

Primary

Measure	Time frame
Six replicate Corneometer CM 825 measurements	8 hours

Secondary

Measure	Time frame
Adverse events	1 day

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026